In addition, recent studies showed MDA5+ DM patients with co-existing anti-Ro52 antibodies had an increased frequency of RPILD and more aggressive phenotypes, highlighting the breach of B cell tolerance likely contributes to the pathogenesis in MDA5+ DM (13, 14). Here, TRIM21 is linked to dermatomyositis.